Why Teladoc Health Stock Is Dropping Thursday Following Soft Q3 Outlook - Teladoc Health (NYSE:TDOC)
Teladoc Health (TDOC) shares fell about 20% in premarket after the company reported Q2 revenue of $606.9 million, down 4% year over year, and guided Q3 revenue to $569 million to $609 million versus a Street view of $629.3 million. Teladoc also forecast a Q3 loss of 30 cents to 20 cents per share.
How this was made
The 30-second read
Why it matters
The combination of a revenue guide miss, wider-than-expected loss guidance, and segment weakness (BetterHelp down 12%) is likely to drive continued repricing and technical selling pressure.
Market read
TDOC’s guidance miss is the fresh fundamental catalyst, and the article also frames near-term technical levels ($8 resistance, $7 support) for trading decisions today.
What to watch
The article highlights BetterHelp weakness and cash-pay pressure, but does not quantify cost actions or longer-term Teladoc One traction that could offset near-term demand wobble.
Background
Teladoc reported Q2 revenue of $606.9M (down 4% YoY) and guided Q3 revenue below Street expectations, citing cash-pay pressure.
Ticker impact
Teladoc guided Q3 revenue to $569M-$609M and a per-share loss wider than expected, driving a sharp premarket drop.
Expect elevated volatility and risk of further downside if price breaks the $7 support area; rebounds may face resistance near $8.
The article cites specific Q2 results, Q3 guidance below consensus, and a large premarket decline, plus nearby support/resistance levels that traders commonly use for near-term positioning.
Market effects
Reinforces that telehealth demand and cash-pay dynamics remain fragile, potentially pressuring similar providers’ near-term sentiment.
Primarily US-listed sentiment impact; no specific regional spillover described.
No direct global catalyst mentioned beyond investor risk appetite for the sector.
Counterpoint
The guidance range still spans $569M-$609M, so traders may look for upside if the low end reflects conservatism rather than deterioration.
Key entities
- companyTeladoc Health
Subject of the article; Q3 revenue and loss guidance below consensus and shares down sharply premarket.
- personChuck Divita
CEO cited Teladoc One as a longer-term product push while acknowledging near-term demand wobble.
